Advertisement

Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy

  • J. Puzo
    Affiliations
    Biochemistry Department, San Jorge Hospital, Huesca, Spain
    Search for articles by this author
  • P. Alfonso
    Affiliations
    Centre for Biomedical Network Research on Rare Disease (CIBERER), Spain

    Institute Aragones of Health Sciences (I+CS), Zaragoza, Spain
    Search for articles by this author
  • P. Irun
    Affiliations
    Centre for Biomedical Network Research on Rare Disease (CIBERER), Spain

    Institute Aragones of Health Sciences (I+CS), Zaragoza, Spain
    Search for articles by this author
  • J. Gervas
    Affiliations
    Centre for Biomedical Network Research on Rare Disease (CIBERER), Spain

    Institute Aragones of Health Sciences (I+CS), Zaragoza, Spain
    Search for articles by this author
  • M. Pocovi
    Affiliations
    Centre for Biomedical Network Research on Rare Disease (CIBERER), Spain

    Institute Aragones of Health Sciences (I+CS), Zaragoza, Spain

    Department of Biochemistry, Molecular and Cellular Biology, University of Zaragoza, Zaragoza, Spain
    Search for articles by this author
  • P. Giraldo
    Correspondence
    Corresponding author at: Pilar Giraldo, S° Hematología, Hospital Universitario Miguel Servet, P° Isabel La Católica 1–3, 50006 Zaragoza, Spain. Tel.: +34 670 285 339; fax: +34 976 468 041.
    Affiliations
    Centre for Biomedical Network Research on Rare Disease (CIBERER), Spain

    Institute Aragones of Health Sciences (I+CS), Zaragoza, Spain

    Hematology Department, Miguel Servet University Hospital, Zaragoza, Spain
    Search for articles by this author

      Abstract

      Objective

      Type 1 Gaucher disease (GD1) is an autosomal recessive lysosomal storage disorder associated with abnormal accumulation of glucocerebrosides. Plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) are decreased in GD1 patients. The effects of substrate reduction therapy (SRT) with miglustat on plasma lipids and atherogenic factors have not yet been examined. Here, we report plasma atherogenic profile data from GD1 patients undergoing long-term SRT.

      Methods

      Plasma was analysed in 26 GD1 patients treated with miglustat for up to 36 months. Ten patients were therapy-naïve and 16 had switched from enzyme replacement therapy (ERT); the interval between stopping ERT and starting SRT was 2–6 weeks. Plasma TC, triglycerides (TG), LDL-c, HDL-c, apolipoproteins (apoA-I, apoB, and Lp[a]), C-reactive protein (CRP) concentrations, and chitotriosidase activity were measured before SRT (baseline) and at 12, 24, and 36 months follow up.

      Results

      In therapy-naïve patients, miglustat significantly increased plasma HDL-c and apoA-I, and slightly increased TC; while TG, CRP concentrations, and TC/HDL-c ratios decreased significantly after 24 months. In contrast, there were no changes in HDL-c and apoA-I, or in the TC/HDL-c ratio in switch patients. However, a decrease in CRP was observed after 12 months. LDL-c and apoB were not significantly altered in either patient group.

      Conclusions

      Miglustat appears to have beneficial effects on plasma lipid, lipoprotein, and CRP concentrations in therapy-naïve GD1 patients, resulting in an improved atherogenic lipid profile. Further studies are required to determine the effect of miglustat on coronary heart disease risk.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Beutler E.
        • Grabowski G.A.
        Gaucher disease.
        in: The metabolic and molecular bases of inherited disease. vol. 3. McGraw-Hill, New York2001: 3635-3668
        • Ginsberg H.
        • Grabowski G.A.
        • Gibson J.C.
        • et al.
        Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease.
        Clin Genet. 1984; 26: 109-116
        • Le N.A.
        • Gibson J.C.
        • Rubinstein A.
        • Grabowski G.A.
        • Ginsberg H.N.
        Abnormalities in lipoprotein metabolism in Gaucher type 1 disease.
        Metabolism. 1988; 37: 240-245
        • Pocovi M.
        • Cenarro A.
        • Civeira F.
        • et al.
        Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia.
        Lancet. 1998; 351: 1919-1923
        • Weinreb N.J.
        • Deegan P.
        • Kacena K.A.
        • et al.
        Life expectancy in Gaucher disease type 1.
        Am J Hematol. 2008; 83: 896-900
        • Cox T.
        • Lachmann R.
        • Hollak C.
        • et al.
        Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
        Lancet. 2000; 355: 1481-1485
        • Heitner R.
        • Elstein D.
        • Aerts J.
        • Weely S.
        • Zimran A.
        Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
        Blood Cells Mol Dis. 2002; 28: 127-133
        • Weinreb N.J.
        • Charrow J.
        • Andersson H.C.
        • et al.
        Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
        Am J Med. 2002; 113: 112-119
        • Pastores G.M.
        • Barnett N.L.
        • Kolodny E.H.
        An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
        Clin Ther. 2005; 27: 1215-1227
        • Aerts J.M.
        • Hollak C.E.
        • Boot R.G.
        • Groener J.E.
        • Maas M.
        Substrate reduction therapy of glycosphingolipid storage disorders.
        J Inherit Metab Dis. 2006; 29: 449-456
        • Giraldo P.
        • Latre P.
        • Alfonso P.
        • et al.
        Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
        Heamatologica. 2006; 91: 703-706
        • Elstein D.
        • Dweck A.
        • Attias D.
        • et al.
        Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
        Blood. 2007; 110: 2296-2301
        • Hollak C.E.
        • van Weely S.
        • van Oers M.H.
        • Aerts J.M.
        Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
        J Clin Invest. 1994; 93: 1288-1292
        • Cenarro A.
        • Pocovi M.
        • Giraldo P.
        • Garcia-Otin A.L.
        • Ordovas J.M.
        Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease.
        Lancet. 1999; 353: 642-643
        • Alfonso P.
        • Cenarro A.
        • Pérez-Calvo J.I.
        • et al.
        Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease.
        Med Clin (Barc). 2003; 120: 641-646
        • de Fost M.
        • Langeveld M.
        • Franssen R.
        • et al.
        Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.
        Atherosclerosis. 2009; 204: 267-272
        • Alfonso P.
        • Aznarez S.
        • Giralt M.
        • Pocovi M.
        • Giraldo P.
        Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain.
        J Hum Genet. 2007; 52: 391-396
        • Zimram A.
        • Kay A.
        • Gelbart T.
        • et al.
        Gaucher's disease clinical, laboratory, radiologic and genetic features of 53 patients.
        Medicine (Balt). 1992; 71: 337-353
        • Navab M.
        • Yu R.
        • Ghasavi N.
        • Huang W.
        • et al.
        High-density lipoprotein: antioxidant and anti-inflammatory properties.
        Curr Atheroscler Rep. 2007; 9: 244-248
        • Linsel-Nitschke P.
        • Tall A.R.
        HDL as a target in the treatment of atherosclerotic cardiovascular disease.
        Nat Rev Drug Discov. 2005; 4: 193-205
        • Lewington S.
        • Whitlock G.
        • Clarke R.
        • et al.
        Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.
        Lancet. 2007; 370: 1829-2183
        • Cox T.M.
        • Aerts J.M.
        • Andria G.
        • et al.
        The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.
        J Inherit Metab Dis. 2003; 26: 513-526
        • Elstein D.
        • Abrahamov A.
        • Hadas-Halpern I.
        • Zimran A.
        Withdrawal of enzyme replacement therapy in Gaucher disease.
        Br J Haematol. 2000; 110: 488-492
        • Danesh J.
        • Collins R.
        • Peto R.
        Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.
        Circulation. 2000; 104: 1108-1113
        • Jenner J.L.
        • Ordovas J.M.
        • Lamon-Fava S.
        • et al.
        Effects of age, sex, and menopausal status on plasma lipoprotein (a) levels. The Framingham Offspring Study.
        Circulation. 1993; 87: 1135-1141
        • Bassuk S.S.
        • Rifai N.
        • Ridker P.M.
        High-sensitivity C-reactive protein: clinical importance.
        Curr Probl Cardiol. 2004; 29: 439-493
      1. NACBLMP Committee Members, Myers GL, Christenson RH, Cushman M et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009; 55:378–384.

        • Du Clos T.W.
        Function of C-reactive protein.
        Ann Med. 2000; 32: 274-278
        • Brooks D.A.
        • Kakavanos R.
        • Hopwood J.J.
        Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.
        Trends Mol Med. 2003; 9: 450-453
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
        J Am Coll Cardiol. 2004; 44: 720-732